Lumos Pharma

$7.18 0.00% ($0.00)
  • 1D
  • 1W
  • 1M
  • 1Y
  • 5Y
  • YTD

Get ready to invest

Subscribe

About Lumos Pharma

Lumos Pharma, Inc., formerly NewLink Genetics Corporation, is a clinical stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics for rare diseases. Its lead product candidate is LUM-201, an oral growth hormone stimulating therapeutic, is in late stage clinical development for the treatment of Pediatric Growth Hormone Deficiency (PGHD). LUM-201 is an orally administered small molecule that promotes the secretion (secretagogue) of Growth Hormone (GH) from the pituitary gland. LUM-201 acts as an agonist of the GH Secretagogue Receptor to stimulate GH release. The Company’s pipeline features development programs in rare diseases associated with growth hormone deficiencies.

Stock Analysis

last close $7.18
1-mo return -1.6%
3-mo return -24.1%
avg daily vol. 51.6T
52-week high 22.49
52-week low 6.8
market cap. $60M
forward pe -
annual div. -
roe -25.6%
ltg forecast -
dividend yield -
annual rev. $0M
inst own. 34.5%
baraka

Subscribe now for daily local and international financial news

Subscribe